Use of Fluconazole in Pulmonary Mycosis : A Case Report

Authors

  • Trowce Lista Nalle Department of Pharmacology, Faculty of Medicine, University of Pelita Harapan

DOI:

https://doi.org/10.19166/med.v7i3.2295

Keywords:

pulmonary mycosis, fluconazole

Abstract

The diagnostic criteria for pulmonary mycosis are long-term use of invasive medical devices, long-term use of broad-spectrum antibiotics and corticosteroids, lung infiltrate images with unfavorable fever after adequate antibiotic treatment, an increase in eosinophil count. Should be considered during patients undergoing hospitalization, from the beginning the antifungal that fluconazole can be used. Fluconazole is recommended for candida infections by the FDA because it is safe, fewer side effects and better tolerated than other antifungal classes.

References

Rozaliyani A, Jusuf A, Hudoyo A, Nawas A, Syahruddin E, Burhan E, et al. Mikosis Paru. Jakarta: Perhimpunan Dokter Paru Indonesia, 2011.

Tanjung A, Keliat EN. Penyakit Paru Karena Jamur. Dalam: Sudoyo AW, Setiyohadi B, Alwi I, Simadibrata M, Setiati S (editor). Buku Ajar Ilmu Penyakit Dalam Jilid III. Edisi 5. Jakarta: Interna Publishing, 2009. h. 2267-73.

Fishman AP, Elias JA, Fishman JA, Grippi MA, Senior RM, Pack AI. Aspergillus, Candida, and Other Opportunistic Mold Infections of the Lung : Fishman’s Pulmonary Diseases and Disorders, 4th edition (e-book). New York: The McGraw-Hill Companies, Inc. 2008: h. 2291-2321.

Setiabudy R, Bahry B. Obat anti jamur. Farmakologi dan Terapi : Departemen Farmakologi dan Terapi FKUI. Edisi 5, cetak tambahan 2011: h. 571-584.

Wendy IS, danny AM, sugantha S et al. Safety and Efficacy of Corticosteroids for the treatment of Septic shock: A systematic review and metaanalysis. Clinical infectious disease.2009;49-93.

Dellinger RP, Levy MM, Carlet JM et al. surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock:2008. Crit Caremed 2008;36:296-327.

Downloads

Additional Files

Published

2020-02-03

Issue

Vol. 7 No. 3 (2018): June 2018 - September 2018

Section

Case Report

License

Authors who publish with this journal agree to the following terms:

1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License (CC-BY-SA 4.0) that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.

3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website). The final published PDF should be used and bibliographic details that credit the publication in this journal should be included.